schliessen

Filtern

 

Bibliotheken

The effect of fluvastatin of hyperlipidemia in renal transplant recipients: a prospective, placebo-controlled study.

Posttransplant hyperlipidemia is a common complication which may affect long term cardiovascular mortality. In this prospective, placebo-controlled study, 19 renal transplant recipients (11 male 8 female, mean age 31.2 ± 8.4 years) with good allograft function (serum creatinine 230 mg/dl and/or LDL-... Full description

Journal Title: International urology and nephrology 2001, Vol.32(4), pp.713-716
Main Author: Türk, S
Other Authors: Yildiz, A , Tükek, T , Akkaya, V , Aras, U , Türkmen, A , Uras, A R , Sever, M S
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0301-1623
Link: http://search.proquest.com/docview/71311549/?pq-origsite=primo
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: proquest71311549
title: The effect of fluvastatin of hyperlipidemia in renal transplant recipients: a prospective, placebo-controlled study.
format: Article
creator:
  • Türk, S
  • Yildiz, A
  • Tükek, T
  • Akkaya, V
  • Aras, U
  • Türkmen, A
  • Uras, A R
  • Sever, M S
subjects:
  • Adolescent–Therapeutic Use
  • Adult–Blood
  • Anticholesteremic Agents–Blood
  • Apolipoproteins–Therapeutic Use
  • Cholesterol–Therapeutic Use
  • Fatty Acids, Monounsaturated–Blood
  • Female–Drug Therapy
  • Fluvastatin–Etiology
  • Humans–Therapeutic Use
  • Hydroxymethylglutaryl-Coa Reductase Inhibitors–Adverse Effects
  • Hyperlipidemias–Blood
  • Indoles–Blood
  • Kidney Transplantation–Blood
  • Lipids–Blood
  • Lipoprotein(a)–Blood
  • Lipoproteins, LDL–Blood
  • Male–Blood
  • Middle Aged–Blood
  • Prospective Studies–Blood
  • Treatment Outcome–Blood
  • Anticholesteremic Agents
  • Apolipoproteins
  • Fatty Acids, Monounsaturated
  • Hydroxymethylglutaryl-Coa Reductase Inhibitors
  • Indoles
  • Lipids
  • Lipoprotein(a)
  • Lipoproteins, LDL
  • Fluvastatin
  • Cholesterol
ispartof: International urology and nephrology, 2001, Vol.32(4), pp.713-716
description: Posttransplant hyperlipidemia is a common complication which may affect long term cardiovascular mortality. In this prospective, placebo-controlled study, 19 renal transplant recipients (11 male 8 female, mean age 31.2 ± 8.4 years) with good allograft function (serum creatinine 230 mg/dl and/or LDL-cholesterol >130 mg/dl) despite dietary interventions. The patients were treated with a triple immunosuppressive regimen. After a 8-week period of placebo plus diet regimen, the patients were put on fluvastatin plus diet for another 8 weeks. The patients were followed for its effect on lipid parameters and side effects. After convertion to fluvastatin, serum cholesterol (263.0 ± 31.6 vs 223.2 ± 31.6 mg/dl, p = 0.001), LDL-cholesterol (174.4 ± 28.3 vs 136.4 ± 28.5 mg/dl, p = 0.002), Apolipoprotein (Apo) A 1 (131.1 ± 16.9 vs 114.7 ± 18.4 mg/dl, p = 0.001) and Apo B (109.0 ± 29.8 vs 97.3 ± 31.5 mg/dl, p = 0.02) levels decreased significantly. Serum levels of triglycerides, VLDL-cholesterol and HDL-cholesterol levels did not vary under fluvastatin. Serum lipoprotein (a) levels were also unchanged during the whole study period (24.9 ± 19.4 vs 23.1 ± 19.8 mg/dl, p > 0.05). We concluded that fluvastatin effectively decreased atherogenic lipoproteins such as serum cholesterol, LDL-cholesterol, Apo B in posttransplant hyperlipidemia, however fluvastatin had no effect on another independent risk factor of atherogenesis, serum lipoprotein (a) levels.
language: eng
source:
identifier: ISSN: 0301-1623
fulltext: fulltext
issn:
  • 03011623
  • 0301-1623
url: Link


@attributes
ID1250393658
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid71311549
sourceidproquest
recordidTN_proquest71311549
sourcesystemPC
pqid71311549
display
typearticle
titleThe effect of fluvastatin of hyperlipidemia in renal transplant recipients: a prospective, placebo-controlled study.
creatorTürk, S ; Yildiz, A ; Tükek, T ; Akkaya, V ; Aras, U ; Türkmen, A ; Uras, A R ; Sever, M S
contributorTürk, S (correspondence author) ; Türk, S (record owner)
ispartofInternational urology and nephrology, 2001, Vol.32(4), pp.713-716
identifierISSN: 0301-1623
subjectAdolescent–Therapeutic Use ; Adult–Blood ; Anticholesteremic Agents–Blood ; Apolipoproteins–Therapeutic Use ; Cholesterol–Therapeutic Use ; Fatty Acids, Monounsaturated–Blood ; Female–Drug Therapy ; Fluvastatin–Etiology ; Humans–Therapeutic Use ; Hydroxymethylglutaryl-Coa Reductase Inhibitors–Adverse Effects ; Hyperlipidemias–Blood ; Indoles–Blood ; Kidney Transplantation–Blood ; Lipids–Blood ; Lipoprotein(a)–Blood ; Lipoproteins, LDL–Blood ; Male–Blood ; Middle Aged–Blood ; Prospective Studies–Blood ; Treatment Outcome–Blood ; Anticholesteremic Agents ; Apolipoproteins ; Fatty Acids, Monounsaturated ; Hydroxymethylglutaryl-Coa Reductase Inhibitors ; Indoles ; Lipids ; Lipoprotein(a) ; Lipoproteins, LDL ; Fluvastatin ; Cholesterol
languageeng
source
descriptionPosttransplant hyperlipidemia is a common complication which may affect long term cardiovascular mortality. In this prospective, placebo-controlled study, 19 renal transplant recipients (11 male 8 female, mean age 31.2 ± 8.4 years) with good allograft function (serum creatinine <2 mg/dl) more than 6 months after transplantation were included. All the patients had hyperlipidemia (serum cholesterol >230 mg/dl and/or LDL-cholesterol >130 mg/dl) despite dietary interventions. The patients were treated with a triple immunosuppressive regimen. After a 8-week period of placebo plus diet regimen, the patients were put on fluvastatin plus diet for another 8 weeks. The patients were followed for its effect on lipid parameters and side effects. After convertion to fluvastatin, serum cholesterol (263.0 ± 31.6 vs 223.2 ± 31.6 mg/dl, p = 0.001), LDL-cholesterol (174.4 ± 28.3 vs 136.4 ± 28.5 mg/dl, p = 0.002), Apolipoprotein (Apo) A 1 (131.1 ± 16.9 vs 114.7 ± 18.4 mg/dl, p = 0.001) and Apo B (109.0 ± 29.8 vs 97.3 ± 31.5 mg/dl, p = 0.02) levels decreased significantly. Serum levels of triglycerides, VLDL-cholesterol and HDL-cholesterol levels did not vary under fluvastatin. Serum lipoprotein (a) levels were also unchanged during the whole study period (24.9 ± 19.4 vs 23.1 ± 19.8 mg/dl, p > 0.05). We concluded that fluvastatin effectively decreased atherogenic lipoproteins such as serum cholesterol, LDL-cholesterol, Apo B in posttransplant hyperlipidemia, however fluvastatin had no effect on another independent risk factor of atherogenesis, serum lipoprotein (a) levels.
version4
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttp://search.proquest.com/docview/71311549/?pq-origsite=primo$$EView_record_in_ProQuest_(subscribers_only)
search
creatorcontrib
0Türk, S
1Yildiz, A
2Tükek, T
3Akkaya, V
4Aras, U
5Türkmen, A
6Uras, A R
7Sever, M S
titleThe effect of fluvastatin of hyperlipidemia in renal transplant recipients: a prospective, placebo-controlled study.
subject
0Adolescent–Therapeutic Use
1Adult–Blood
2Anticholesteremic Agents–Blood
3Apolipoproteins–Therapeutic Use
4Cholesterol–Therapeutic Use
5Fatty Acids, Monounsaturated–Blood
6Female–Drug Therapy
7Fluvastatin–Etiology
8Humans–Therapeutic Use
9Hydroxymethylglutaryl-Coa...
general
0English
1MEDLINE (ProQuest)
2ProQuest Biological Science Collection
3ProQuest Natural Science Collection
4ProQuest SciTech Collection
5Biological Science Database
6Natural Science Collection
7SciTech Premium Collection
8Health Research Premium Collection
9Health Research Premium Collection (Alumni edition)
10Biological Science Index (ProQuest)
sourceidproquest
recordidproquest71311549
issn
003011623
10301-1623
rsrctypearticle
creationdate2001
addtitleInternational urology and nephrology
searchscope
01007527
11007944
21009130
310000004
410000038
510000050
610000120
710000159
810000238
910000253
1010000260
1110000270
1210000271
1310000302
1410000350
15proquest
scope
01007527
11007944
21009130
310000004
410000038
510000050
610000120
710000159
810000238
910000253
1010000260
1110000270
1210000271
1310000302
1410000350
15proquest
lsr43
01007527false
11007944false
21009130false
310000004false
410000038false
510000050false
610000120false
710000159false
810000238false
910000253false
1010000260false
1110000270false
1210000271false
1310000302false
1410000350false
contributorTürk, S
startdate20010101
enddate20010101
citationpf 713 pt 716 vol 32 issue 4
lsr30VSR-Enriched:[doi, description, pqid, eissn]
sort
titleThe effect of fluvastatin of hyperlipidemia in renal transplant recipients: a prospective, placebo-controlled study.
authorTürk, S ; Yildiz, A ; Tükek, T ; Akkaya, V ; Aras, U ; Türkmen, A ; Uras, A R ; Sever, M S
creationdate20010101
lso0120010101
facets
frbrgroupid2544212169347676322
frbrtype5
newrecords20181218
languageeng
creationdate2001
topic
0Adolescent–Therapeutic Use
1Adult–Blood
2Anticholesteremic Agents–Blood
3Apolipoproteins–Therapeutic Use
4Cholesterol–Therapeutic Use
5Fatty Acids, Monounsaturated–Blood
6Female–Drug Therapy
7Fluvastatin–Etiology
8Humans–Therapeutic Use
9Hydroxymethylglutaryl-Coa...
collection
0MEDLINE (ProQuest)
1ProQuest Biological Science Collection
2ProQuest Natural Science Collection
3ProQuest SciTech Collection
4Biological Science Database
5Natural Science Collection
6SciTech Premium Collection
7Health Research Premium Collection
8Health Research Premium Collection (Alumni edition)
9Biological Science Index (ProQuest)
prefilterarticles
rsrctypearticles
creatorcontrib
0Türk, S
1Yildiz, A
2Tükek, T
3Akkaya, V
4Aras, U
5Türkmen, A
6Uras, A R
7Sever, M S
jtitleInternational urology and nephrology
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Türk
1Yildiz
2Tükek
3Akkaya
4Aras
5Türkmen
6Uras
7Sever
aufirst
0S
1A
2T
3V
4U
5A R
6M S
au
0Türk, S
1Yildiz, A
2Tükek, T
3Akkaya, V
4Aras, U
5Türkmen, A
6Uras, A R
7Sever, M S
addauTürk, S
atitleThe effect of fluvastatin of hyperlipidemia in renal transplant recipients: a prospective, placebo-controlled study.
jtitleInternational urology and nephrology
risdate20010101
volume32
issue4
spage713
epage716
pages713-716
issn0301-1623
formatjournal
genrearticle
ristypeJOUR
urlhttp://search.proquest.com/docview/71311549/
doi10.1023/A:1015052312866
eissn15732584
date2001-01-01